Program Brochure

Short Course  October 12, 2017

  1. Haoda Fu, Research Advisor, Eli Lilly and Company, Artificial Intelligence, Machine Learning, and Precision Medicine (9:00am to 12:00pm)
  2. Frank Bretz, Global Head of the Statistical Methodology and Consulting Group, Novartis, MCP-Mod: A Statistical Approach to Design and Analyze Phase II Dose Finding Studies (1:30pm to 4:30pm)


Main Program  October 13, 2017

  8:00  –  9:00 am Registration (Foyer) and Breakfast (Foyer and Glen Ballroom)
  9:00  –  9:10 am
Opening Remarks (Glen Ballroom)

Li Wang (AbbVie), Alan Rong (Astellas)

  9:10– 9:30 am Keynote Address (Glen Ballroom)
Opportunities for statisticians in the era of big data and precision medicine Ivan Chan (AbbVie Inc.)
  9:30– 9:50 am Keynote Address (Glen Ballroom)
A few thoughts from an old statistician: how to make a difference without chasing the next shinny thing Kevin Chartier (Astellas Pharma Inc.)
9:50– 10:20 am Keynote Address (Glen Ballroom)
How the ICH E9 addendum around estimands may impact our clinical trials Frank Bretz (Novartis)
10:15–10:30 am Break/Networking
10:45 –12:00 am Parallel Session 1 (Salon C)

Real World Evidence (RWE) and its applications in clinical development

Parallel Session 2 (Salon D)

Analysis methods in clinical trial monitoring

12:00 – 1:00 pm Lunch (Garden Atrium)
8:00am – 4:00 pm Student Poster Session  (Foyer)
12:45 – 1:30 pm Student Poster Q&A Session (Foyer)
12:45 – 1:30 pm Student Interview (Board Room)
  1:30 – 2:45 pm Parallel Session 3 (Salon C)
Biomarker discovery and new technology
Parallel Session 4 (Salon D)
Joint model and dynamic prediction
  2:45 –  3:00 pm Break/Networking
  3:00 – 4:15 pm Parallel Session 5 (Salon C)
Subgroup identification and other statistical issues in clinical trial practice
Parallel Session 6 (Salon D)
Variable selection and nonparametric methods
  4:20 –4:45 pm Student Awards and Closing Remarks (Salon D)
 Lei Liu (Washington University in St. Louis)Alan Rong (Astellas Pharma Inc.)

Li Wang (AbbVie Inc.)